Respiratory Disease Genetic Testing Market

Grifols signed on as an inaugural industry sponsor of AlphaDetect, the Alpha-1 Foundation’s free testing laboratory, in a release dated 5 June 2026, and the announcement notes that more than 90% of people with alpha-1 are still unidentified. Respiratory disease genetic testing covers germline tests that confirm, rule out or predict inherited lung disease, from CFTR and SERPINA1 genotyping to sequencing panels for ciliary, fibrotic and vascular disorders. Douglas Insights sizes the Respiratory Disease Genetic Testing Market at USD 732.7 million in 2025, from 4.27 million tests at an average realised USD 171.6 each, rising to USD 1.55 billion by 2035 at 7.78% a year. The work sits inside our in-vitro diagnostics coverage, and every step of the build follows the Douglas Insights research methodology.

Which laboratories and companies win respiratory disease genetic testing volume in 2025?

Reference laboratories win most respiratory disease genetic testing volume: Douglas Insights estimates the top three, Labcorp, Quest Diagnostics and GeneDx, hold 38.6% of 2025 revenue. Sponsor-funded alpha-1 programmes and test makers share the rest of the USD 732.7 million pool.

Labcorp built its position on scale and on its purchase of select Invitae assets, finalised on 5 August 2024; the company says it performs more than 600 million tests a year, and the Invitae assets widened its rare disease and specialty genetics menu. Douglas Insights estimates Labcorp alone takes 16.2% of respiratory disease genetic testing revenue.

GeneDx is the exome and genome specialist. Its fourth quarter 2025 release of 23 February 2026 reported 97,271 exome and genome results for 2025 and USD 360.3 million of exome and genome revenue, which works out at about USD 3,704 per result. Only a small slice of that volume is respiratory, yet pulmonary hypertension, surfactant and ciliary cases are referred through the same sequencing route.

Quest Diagnostics sells carrier screening that places cystic fibrosis inside the minimum panel of the American College of Obstetricians and Gynecologists (ACOG). Natera reaches the same prenatal buyers through its Horizon carrier screen. Illumina supplies the sequencer side, including the MiSeqDx Cystic Fibrosis System used for CFTR carrier screening and diagnosis.

Grifols is the alpha-1 anchor. Its programme has screened more than 1.5 million people, and its AlphaID At Home saliva service checks 14 SERPINA1 variants. Douglas Insights puts sponsor-funded alpha-1 testing, led by Grifols and AlphaDetect, at 9.7% of 2025 respiratory disease genetic testing revenue.

Which inherited lung disease segment leads respiratory disease genetic testing revenue?

Cystic fibrosis leads with 41.7% of respiratory disease genetic testing revenue, or USD 305.5 million in 2025, because CFTR testing runs through both prenatal carrier screening and newborn diagnosis in every major market. Alpha-1 testing follows at 21.4%, and four rarer disorders share the remaining 36.9%.

Cystic fibrosis testing, worth USD 305.5 million, grows 6.1% a year to USD 552.3 million. Its base is mature, but the Cystic Fibrosis Foundation counts about 1,000 new US diagnoses a year and more than 1,700 known CFTR mutations, so confirmatory sequencing keeps adding value per case.

Alpha-1 antitrypsin deficiency testing is the fastest-growing segment at 10.3% a year, from USD 156.8 million to USD 417.9 million. MedlinePlus puts alpha-1 at 1 in 1,500 to 3,500 people of European ancestry, and with more than 90% undiagnosed, every sponsored case-finding drive pulls new SERPINA1 tests.

Interstitial lung disease and pulmonary fibrosis panels hold 12.8%, or USD 93.8 million. About 100,000 Americans have idiopathic pulmonary fibrosis, and TERT and TERC mutations explain about 15% of familial cases, so telomere gene panels are spreading from research into clinic, at 9.2% a year.

Primary ciliary dyskinesia carries 9.3% (USD 68.1 million). MedlinePlus counts more than 50 causative genes and a prevalence as high as 1 in 7,500, which makes a panel the only practical first test.

Pulmonary arterial hypertension testing holds 7.6%, or USD 55.7 million, growing 7.2% a year as heritable cases are referred to exome sequencing. Surfactant dysfunction and other rare disorders add USD 52.8 million, a 7.2% share that grows slowest at 5.7% because the patient pool is mostly neonatal and small.

By technology, targeted genotyping still handles most single-gene work, next-generation sequencing panels carry the multigene disorders, and exome and genome sequencing take the unsolved cases. By end user, reference laboratories dominate, hospital laboratories run newborn and confirmatory work, and direct-to-consumer kits now reach adults at home.

Why is respiratory disease genetic testing volume rising 6.4% a year?

Respiratory disease genetic testing volume rises 6.4% a year because four forces stack: alpha-1 case finding adds 2.3 points, multigene panels 1.8, CFTR genotyping for modulator eligibility 1.6 and Asia Pacific laboratory build-out 0.7. Together the four drivers lift tests from 4.27 million in 2025 to 7.94 million by 2035, across all five regions.

Alpha-1 case finding is the largest driver at 2.3 points. Grifols’ AlphaID At Home won US Food and Drug Administration (FDA) clearance on 3 November 2022 as a free direct-to-consumer service, and Grifols said the test had already been available to physicians since 2018. The 2026 sponsorships of AlphaDetect by Grifols and Wave Life Sciences add a free laboratory route. Douglas Insights expects SERPINA1 tests to climb from about 0.73 million in 2025 to 1.9 million by 2035 as case finding moves into chronic obstructive pulmonary disease (COPD) clinics, where the CDC estimates about 16 million Americans already carry a diagnosis.

Multigene panels contribute 1.8 points. Primary ciliary dyskinesia spans more than 50 genes and pulmonary fibrosis more than 20, so the single-gene test is giving way to the panel. Douglas Insights counts multigene panels at 12.6% of 2025 test volume but 45.5% of revenue, because one panel replaces three or four sequential single-gene orders.

CFTR genotyping tied to treatment adds 1.6 points. Vertex’s once-daily ALYFTREK won European Commission approval, announced on 1 July 2025, for people aged 6 and older with at least one non-class I CFTR mutation, and Vertex said about 31,000 people in the EU became eligible. A genotype is the entry ticket to every modulator prescription, so each label expansion sends patients back for full CFTR sequencing.

Asia Pacific laboratory build-out adds the last 0.7 points. The region starts small, at USD 120.2 million, but grows 10.37% a year as hospital laboratories add next-generation sequencing and as carrier screening reaches urban prenatal clinics.

Diagnostic yield keeps the drivers honest. Douglas Insights assumes an affected or carrier result in about 4.8% of respiratory disease genetic testing orders in 2025, and each positive triggers cascade testing of two to three relatives on average, so every new index case multiplies downstream volume.

Births anchor the prenatal base. The US registered 3,628,934 births in 2024, according to the National Center for Health Statistics, and Douglas Insights models the CF component of carrier screening on that birth cohort plus comparable European cohorts. Volume is the engine here, not price: the 6.4% volume leg is nearly five times the 1.3% price leg.

Which payer and counselling hurdles slow respiratory disease genetic testing?

Three hurdles slow respiratory disease genetic testing and remove 2.3 points from volume growth in the slower case. Payer coverage rules, scarce genetic counselling and variant uncertainty leave 2035 revenue at USD 1.16 billion in that case, against USD 1.55 billion in the base case.

Payer coverage is the biggest drag, worth 1.1 points. US commercial medical policies for alpha-1 testing typically restrict coverage to patients with emphysema, unexplained liver disease or a known affected relative, so population-wide screening relies on free sponsored kits. Douglas Insights estimates 28.4% of alpha-1 tests in 2025 were paid by sponsors rather than insurers.

Genetic counselling capacity removes 0.7 points. Panels for interstitial lung disease and ciliary disorders return variants of uncertain significance in a meaningful minority of cases, and each needs a counsellor or a pulmonologist trained to interpret it. Waiting lists delay orders more than they cancel them.

Variant interpretation in non-European populations removes 0.5 points. CFTR and SERPINA1 variant panels were built on European ancestry, so detection rates fall in Latin America, the Middle East and Asia, and laboratories there must sequence the full gene, at three to five times the cost of a genotyping assay.

Where does North America lead respiratory disease genetic testing, and which region grows fastest?

North America leads respiratory disease genetic testing with USD 339.2 million in 2025, a 46.3% share, because carrier screening and alpha-1 case finding are routine there and reference laboratories run national logistics. Europe ranks second at 28.9%, and Asia Pacific grows fastest at 10.37% a year.

North America grows 7.04% a year to USD 669.8 million by 2035. Europe follows at USD 211.8 million, growing 7.21% to USD 424.9 million, carried by CF newborn screening and modulator genotyping across the EU. Asia Pacific is the fastest-growing region at 10.37% a year, from USD 120.2 million to USD 322.4 million, as sequencing capacity spreads into hospital laboratories.

Latin America holds USD 35.9 million and grows 8.83% a year to USD 83.7 million. The Middle East and Africa is the wildcard: USD 25.6 million today, rising 6.84% a year to USD 49.6 million, where consanguinity raises recessive disease rates yet coverage of genetic tests remains thin.

How much do laboratories charge per respiratory disease genetic test?

Respiratory disease genetic testing averaged USD 171.6 per test in 2025, a blend of cheap genotyping and expensive sequencing; Douglas Insights expects that average to reach USD 195.3 by 2035 at 1.3% a year. Realised prices run from zero to the patient on sponsored alpha-1 kits up to about USD 4,200 for an exome.

Douglas Insights price bands are realised payer and sponsor rates, not list prices. GeneDx’s disclosed figures imply about USD 3,704 per exome or genome result in 2025, which sets the top of the range. At the bottom, AlphaID At Home and AlphaDetect cost the patient nothing: the sponsor pays the laboratory, and our model counts that payment as revenue.

The 1.3% price leg is slow on purpose. Sequencing costs keep falling, but the mix shifts towards panels and exomes, which lifts the blended respiratory disease genetic testing price by about USD 2.2 a year in the base case.

Are next-generation sequencing panels replacing targeted genotyping in respiratory disease genetic testing?

Next-generation sequencing panels are taking share but not replacing genotyping: Douglas Insights counts panels and sequencing at 17.9% of 2025 respiratory disease genetic testing volume, rising to 26.8% by 2035. Genotyping keeps the cheap, high-volume carrier and alpha-1 screens, while sequencing takes rare and unsolved cases.

Targeted genotyping survives because it is cheap and fast. A carrier screen or a SERPINA1 allele check answers a narrow question, and for most COPD patients or expectant parents the answer is negative. Sequencing is reserved for positives, unresolved phenotypes and the rare disorders where no common variant exists.

Exome and genome sequencing is the long tail. Pulmonary arterial hypertension and surfactant dysfunction cases often reach sequencing after a panel fails, and each such result earns twenty times the revenue of a genotype.

What would push the respiratory disease genetic testing forecast above or below USD 1.55 billion in 2035?

Respiratory disease genetic testing reaches USD 1.55 billion in the base case by 2035, against USD 1.16 billion in a slower case and USD 1.94 billion in a faster one. Alpha-1 case finding and payer coverage decide most of the USD 781.4 million gap between them.

Sensitivity is high. A single extra point of annual test growth adds about USD 152.0 million to the 2035 respiratory disease genetic testing total, which is why the alpha-1 programmes matter so much.

The faster case assumes the AlphaDetect model, backed by Grifols from 5 June 2026 as the Alpha-1 Foundation release records, spreads to European COPD clinics and that panel testing becomes standard for fibrotic lung disease. The slower case assumes payers keep alpha-1 coverage narrow and sponsors pull back.

Published forecasts for adjacent genetic testing markets run from about 5.3% to 22.8% a year. Our 7.78% sits toward the lower end because respiratory testing leans on low-priced genotyping, not oncology sequencing.

Which FDA rules and laboratory standards govern respiratory disease genetic testing?

Two regulatory routes govern respiratory disease genetic testing in the US: FDA clearance for kits and direct-to-consumer services, and laboratory oversight for laboratory-developed tests, which FDA stopped treating as devices on 19 September 2025. Most respiratory panels are built in-house, so that change matters more here than in kit-based diagnostics.

The FDA’s Federal Register notice of 19 September 2025 removed the May 2024 laboratory-developed test language from 21 CFR 809.3(a), after the US District Court for the Eastern District of Texas vacated that rule on 31 March 2025. For respiratory panels, most of which are built in-house, that removes a premarket review burden Douglas Insights had costed at 0.4 points of annual volume growth.

Direct-to-consumer tests still need FDA authorisation. AlphaID At Home was Grifols’ first clearance for direct-to-consumer use, and its user comprehension study enrolled 525 participants. In the EU, CFTR genotyping for modulators follows the drug label, so each new approval effectively writes a testing requirement.

Douglas Exclusive: the Respiratory Genetic Testing Catalyst Calendar

The Catalyst Calendar is a Douglas Insights model, built from 10 dated, sourced events and 14 sourced inputs, that converts each event into tests added in the base case. The calendar is our own construction, not an official register. It covers 2025 to 2035 and all six disease segments.

Respiratory disease genetic testing volume, on this calendar, reaches 7.94 million tests by 2035. The finding: 31.9% of the added tests come from alpha-1 case finding, more than from cystic fibrosis, even though CF carries 41.7% of today’s revenue.

Our calendar ranks catalysts by tests added, not by headline. Sponsored free testing scores higher than any single drug approval, because it removes the payer gate entirely.

How the model builds 4.27 million respiratory disease genetic tests into USD 732.7 million?

Respiratory disease genetic testing revenue equals 4.27 million tests times USD 171.6, which gives USD 732.7 million for 2025; volume grows 6.4% and price 1.3% a year, compounding to 7.78%. Every input is sourced or labelled as our estimate, across six segments and five regions.

The model splits six disease segments and five regions. Test counts start from 3,628,934 US births in 2024, 109,000 people with cystic fibrosis worldwide, alpha-1 prevalence of 1 in 1,500 to 3,500 in European ancestry, about 100,000 Americans with pulmonary fibrosis and a primary ciliary dyskinesia prevalence of 1 in 7,500.

Two cross-checks hold. GeneDx’s implied USD 3,704 per exome or genome result sits inside our USD 2,500 to USD 4,200 band, and the six segment forecasts sum to USD 1.55 billion in 2035, within 0.14% of the USD 1.55 billion total. Regions sum exactly to USD 732.7 million in 2025 and USD 1.55 billion in 2035. Inside the blended USD 171.6 price, genotyping averages about USD 65.7, panels USD 620, full gene sequencing USD 420 and exomes USD 2,900.

Should buyers of respiratory disease genetic testing plan around alpha-1 or cystic fibrosis?

Plan around both, but weight alpha-1: SERPINA1 testing grows 10.3% a year against 6.1% for CFTR, and adds USD 261.1 million of respiratory disease genetic testing revenue by 2035. Cystic fibrosis stays the larger line, but alpha-1 adds the most new tests and the faster revenue.

Laboratories should price panels for fibrotic and ciliary disease now, while volumes are small. Kit suppliers should watch sponsored programmes, because free testing changes who pays. Readers tracking adjacent lines can compare our Digital PCR Market, the Smart Inhalers Market and the Acute Respiratory Distress Syndrome (ARDS) Market.

Sources

1. Alpha-1 Foundation Grifols supports AlphaDetect (2026)
2. Grifols FDA clearance for AlphaID At Home (2022)
3. Labcorp Labcorp finalizes acquisition of select assets of Invitae (2024)
4. Vertex Pharmaceuticals European Commission approval of ALYFTREK (2025)
5. Federal Register Laboratory Developed Tests; Implementation of Vacatur (2025)
6. GeneDx GeneDx fourth quarter and full year 2025 results (2026)
7. CDC NCHS Births in the United States, 2024 (2025)
8. MedlinePlus Genetics Alpha-1 antitrypsin deficiency (2025)